Get the Stockscreener App
8.20
4.88%
0.41
Actuate Therapeutics Inc stock is traded at $8.20, with a volume of 4,002.
It is up +4.88% in the last 24 hours and up +22.49% over the past month.
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
See More
Previous Close:
$7.79
Open:
$7.78
24h Volume:
4,002
Relative Volume:
0.05
Market Cap:
$189.90M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+16.38%
1M Performance:
+22.49%
6M Performance:
+6.66%
1Y Performance:
+11.16%
1-Day Range:
$7.78
$8.3037
1-Week Range:
$6.87
$8.49
52-Week Range:
$5.47
$11.99
Actuate Therapeutics Inc Stock (ACTU) Company Profile
Name
Actuate Therapeutics Inc
Sector
Industry
Phone
847-986-4190
Address
1751 RIVER RUN, FORT WORTH
Compare ACTU with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACTU
Actuate Therapeutics Inc
|
8.17 | 181.07M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
405.64 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.22 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
542.01 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
795.45 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
326.40 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Actuate Therapeutics Inc Stock (ACTU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-26-25 | Initiated | B. Riley Securities | Buy |
| Apr-22-25 | Initiated | Craig Hallum | Buy |
| Mar-17-25 | Initiated | H.C. Wainwright | Buy |
Actuate Therapeutics Inc Stock (ACTU) Latest News
How to forecast Actuate Therapeutics Inc. trends using time series2025 Earnings Surprises & Technical Buy Zone Confirmations - newser.com
Risk vs reward if holding onto Actuate Therapeutics Inc.Dollar Strength & Real-Time Market Trend Scan - newser.com
How hedge fund analytics apply to Actuate Therapeutics Inc. stock2025 Market Sentiment & Free High Accuracy Swing Entry Alerts - newser.com
Will Actuate Therapeutics Inc. stock see insider buyingPortfolio Risk Report & Fast Exit and Entry Trade Guides - newser.com
Can Actuate Therapeutics Inc. stock deliver sustainable ROETrade Exit Summary & Low Risk Profit Maximizing Plans - newser.com
Reversal indicators forming on Actuate Therapeutics Inc. stock2025 Valuation Update & Daily Chart Pattern Signal Reports - newser.com
Myelofibrosis Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates | Lynk Pharma, Samus Therapeutics, Taiga Biotech, Bristol-Myers Squibb, Sumitomo Pharma Oncology, Keros - Barchart.com
Using Bollinger Bands to evaluate Actuate Therapeutics Inc.Weekly Trading Summary & Weekly Setup with ROI Potential - newser.com
Actuate Therapeutics (NASDAQ:ACTU) Receives Sell (D-) Rating from Weiss Ratings - MarketBeat
Applying Elliott Wave Theory to Actuate Therapeutics Inc.2025 Momentum Check & Expert Curated Trade Ideas - newser.com
Price action breakdown for Actuate Therapeutics Inc.Market Volume Report & Growth Focused Investment Plans - newser.com
Is Actuate Therapeutics Inc. trending in predictive chart models2025 Big Picture & Free Daily Entry Point Trade Alerts - newser.com
Evaluating Actuate Therapeutics Inc. with trendline analysisJuly 2025 Patterns & Weekly Top Gainers Trade List - newser.com
How to build a custom watchlist for Actuate Therapeutics Inc.2025 Top Decliners & AI Based Buy and Sell Signals - newser.com
Is Actuate Therapeutics Inc. forming a reversal patternWeekly Earnings Recap & Low Risk Investment Opportunities - newser.com
Craig-Hallum Maintains Actuate Therapeutics(ACTU.US) With Buy Rating - 富途牛牛
H.C. Wainwright Maintains Actuate Therapeutics(ACTU.US) With Buy Rating, Maintains Target Price $20 - 富途牛牛
B.Riley Financial Initiates Actuate Therapeutics(ACTU.US) With Buy Rating, Announces Target Price $20 - 富途牛牛
Pancreatic Cancer Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Dragonfly Therapeutics, Keymed B, Tango Therapeutics, Atara Bio, Keymed Biosciences, Carisma Therapeu - Barchart.com
Relative strength of Actuate Therapeutics Inc. in sector analysisPortfolio Return Report & AI Enhanced Execution Alerts - newser.com
Published on: 2025-10-02 23:42:39 - newser.com
Ataxia Telangiectasia Market Dynamics Indicate Upward Trajectory Through 2034, Reports DelveInsight - openPR.com
Actuate Therapeutics Inc Stock Analysis and ForecastHigh Beta Stocks & Budget Friendly Investment Plans - earlytimes.in
Goldman Sachs Group Inc. Has $151,000 Holdings in Actuate Therapeutics, Inc. $ACTU - Defense World
Myelofibrosis Market Outlook 2034 – Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight - Barchart.com
Myelofibrosis Market Outlook 2034Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight - openPR.com
Published on: 2025-09-29 03:19:58 - newser.com
What analysts say about Actuate Therapeutics Inc stockShort-Term Trading Alerts & Trade Like a Pro Using AI Edge - Early Times
Actuate Therapeutics Inc Stock (ACTU) Financials Data
There is no financial data for Actuate Therapeutics Inc (ACTU). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Actuate Therapeutics Inc Stock (ACTU) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kreis Leslie W. | Director |
Jun 27 '25 |
Buy |
7.00 |
71,428 |
499,996 |
196,428 |
| Fletcher Aaron G.L. | Director |
Jun 27 '25 |
Buy |
7.00 |
71,428 |
499,996 |
196,428 |
2.36%
0.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):